r.rotation.to⌕ Search stocks, people, sectors
Request a free account

Follow the people · Insider

EK

Edward M. Kaye

Insider · Director · STOK

Edward M. Kaye files insider transactions with the SEC as a ceo of Stoke Therapeutics (STOK). We hold 2 disclosed purchases and sales filed since 20 June 2011, 1 of them in the last 90 days.

  • Files forSTOK
  • Disclosed buys and sells2 in all, 1 in the last 90 days
  • Last disclosure18 August 2026

Positions held

6 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 16 December 2019 — 18 August 2026CEO · Stoke Therapeutics (STOK)90 Form 4 lines · source: SEC Form 4
  • Filed 18 May 2016 — 15 July 2026Director · Cytokinetics (CYTK)70 Form 4 lines · source: SEC Form 4
  • Filed 27 February 2026 — 27 February 2026Director · Avidity Biosciences (RNAM)16 Form 4 lines · source: SEC Form 4
  • Filed 16 June 2021 — 10 June 2025Director · Avidity Biosciences (RNA)6 Form 4 lines · source: SEC Form 4
  • Filed 23 August 2012 — 3 August 2017President & CEO · Sarepta Therapeutics (SRPT)46 Form 4 lines · source: SEC Form 4
  • Filed 20 June 2011 — 24 April 2012SVP & Chief Medical Officer · Avi Biopharma (AVII)2 Form 4 lines · source: SEC Form 4

Everything they disclosed

120 entries, newest first — one per disclosure report, one per Form 4 line

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.